The U.S. government’s Medicare program on January 11 said it plans to cover Alzheimer’s treatments including Biogen Inc.’s Aduhelm, with some conditions.
Biogen announced that effective January 1, 2022, the company will cut the wholesale acquisition cost of the Alzheimer’s drug Aduhelm (aducanumab) in half.
Massive layoffs could be headed to Biogen due to the disappointing rollout of the company’s Alzheimer’s drug Aduhelm that generated only a few million dollars in revenue over the past two quarters.
Almost one year after Biogen forged a collaboration with Sage Therapeutics worth $1.52 billion, the development deal for the experimental major depressive disorder treatment zuranolone is bearing fruit that will support an expected rolling New Drug Application during 2022.
Biogen Inc.’s Aduhelm – approved by U.S. regulators during 2020 for the ability of the Alzheimer’s drug to reduce amyloid brain plaques – also lowers levels of a second protein that accumulates in the brains of people with the disease, according to new data released by the company on November 11.
Eisai and Biogen announced positive updates on the Phase IIB 201 and open-label extension (OLE) studies they are conducting on the use of lecanemab to treat early Alzheimer’s Disease (AD).
Biogen announced plans to present data on the company’s portfolio, including the controversial medicine Aduhelm (aducanumab), at the annual Clinical Trials on Alzheimer’s Disease conference (CTAD) scheduled for November 9-12.
Biogen Inc. is pinning hopes on a decision on U.S. government coverage of the company’s Alzheimer’s disease drug during 2022 to help drive up Aduhelm’s usage, after a big miss on third-quarter 2021 sales of the much-awaited treatment.
A late-stage trial of Biogen Inc.’s experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) failed to reach the study’s main goal, but secondary measures and biomarkers showed favorable trends, the company said on Oct. 17.
Acting U.S. Food and Drug Administration Commissioner Janet Woodcock’s days as interim head of the regulatory agency are numbered due to federal regulations. Not only does President Biden have to appoint a new FDA commissioner, he will also need to tap a new head of the National Institutes of Health (NIH) following the retirement announcement of longtime director Francis S. Collins, M.D., Ph.D.
